For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $7.33 in the last session, down -3.30% from day before closing price of $7.58. In other words, the price has decreased by -$3.30 from its previous closing price. On the day, 2.4 million shares were traded. OCUL stock price reached its highest trading level at $7.47 during the session, while it also had its lowest trading level at $7.01.
Ratios:
We take a closer look at OCUL’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.59 and its Current Ratio is at 10.66. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $17.
On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 24 ’25 when Dugel Pravin sold 21,475 shares for $6.87 per share. The transaction valued at 147,533 led to the insider holds 3,520,318 shares of the business.
Heier Jeffrey S. sold 3,061 shares of OCUL for $21,029 on Feb 24 ’25. The Chief Scientific Officer now owns 265,998 shares after completing the transaction at $6.87 per share. On Feb 24 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 3,009 shares for $6.87 each. As a result, the insider received 20,672 and left with 210,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1207038464 and an Enterprise Value of 849314048. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.29 while its Price-to-Book (P/B) ratio in mrq is 3.67. Its current Enterprise Value per Revenue stands at 13.328 whereas that against EBITDA is -5.008.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.46, which has changed by -0.1356132 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $11.77, while it has fallen to a 52-week low of $4.06. The 50-Day Moving Average of the stock is -2.64%, while the 200-Day Moving Average is calculated to be -13.02%.
Shares Statistics:
According to the various share statistics, OCUL traded on average about 1.23M shares per day over the past 3-months and 1645440 shares per day over the past 10 days. A total of 157.75M shares are outstanding, with a floating share count of 133.91M. Insiders hold about 15.79% of the company’s shares, while institutions hold 72.51% stake in the company. Shares short for OCUL as of 1741910400 were 12832340 with a Short Ratio of 10.42, compared to 1739491200 on 11601339. Therefore, it implies a Short% of Shares Outstanding of 12832340 and a Short% of Float of 8.1.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
